
Flu virus readily gains resistance to current and new antivirals
Pandemics are an inevitable feature of influenza virus. Current antivirals work by directly targeting influenza virus proteins, such as viral neuraminidase and polymerase, and are highly vulnerable to resistance development due to mutations.
In such eventualities, both seasonal vaccines and existing antivirals are of limited value. Thus, there is the unmet need for antivirals to be more effective and resistant to viral mutations.
This technology developed at the University of Nottingham comprises a small molecule that stimulates a highly effective host antiviral response against influenza virus and respiratory syncytial virus (RSV) which includes interference of viral protein transport and assembly, and enhanced type I and III interferon response. The compound can be orally administered, and is difficult for virus to overcome by mutation.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.